Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Idiopathic Constipation Clear all
Completed Phase 3 Interventional Results available

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

NCT02481947
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
BLI400 Laxative, Lubiprostone
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 10, 2026, 4:10 PM EST
Terminated Not applicable Interventional

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254
View directory record Official record
Conditions
Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting
Interventions
Domperidone
Drug
Lead sponsor
Carle Physician Group
Individual
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

NCT03120520
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Nov 10, 2026, 4:10 PM EST
Completed Not applicable Interventional

Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC)

NCT05129618
View directory record Official record
Conditions
Constipation Chronic Idiopathic
Interventions
MHS 1031, placebo
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

NCT01372423
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Anchen Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
79
States / cities
Dothan, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

NCT01895543
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

NCT05652205
View directory record Official record
Conditions
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions
Placebo for Linaclotide, Linaclotide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 10, 2026, 4:10 PM EST
Active, not recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

12-Week Study of Plecanatide for CIC (The CIC3 Study)

NCT01982240
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Placebo, Bisacodyl
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
177
States / cities
Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

NCT02122471
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
167
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Nov 10, 2026, 4:10 PM EST
Terminated Phase 3 Interventional Results available

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

NCT01827592
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg, Elobixibat 5 mg, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Nov 10, 2026, 4:10 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

NCT01833065
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg/day, Elobixibat 5 mg/day, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
lubiprostone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 4 Interventional Results available

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

NCT02590432
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
79
States / cities
Anniston, Alabama • Athens, Alabama • Childersburg, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 2 Interventional

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

NCT01989234
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
YKP10811, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

NCT00306748
View directory record Official record
Conditions
Constipation
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Boynton Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

NCT02819297
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, CIC
Interventions
BLI400 Laxative, BLI400 Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)

NCT04458675
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Vibrant capsule, Placebo
Device · Drug
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Nov 10, 2026, 4:10 PM EST
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 10, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

NCT03879239
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Vibrating capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Foley, Alabama • Tucson, Arizona • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

NCT01993875
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Anniston, Alabama • Anaheim, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 4 Interventional

Sacral Nerve Stimulation for Anal Incontinence and Bowel Control

NCT00200005
View directory record Official record
Conditions
Fecal Incontinence and Constipation
Interventions
Type: Implantable neurostimulator; InterStim
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 3 Interventional

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

NCT01674530
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
93
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Nov 10, 2026, 4:10 PM EST
Completed Phase 2Phase 3 Interventional Results available

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

NCT01429987
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
plecanatide, Placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Nov 10, 2026, 4:10 PM EST